N-Methyl-2-(methylamino)-1,3-thiazole-4-carboxamide | 1365272-30-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-Methyl-2-(methylamino)-1,3-thiazole-4-carboxamide
• CAS: 1365272-30-5
• 化学式: C₆H₉N₃OS
• 分子量: 171.22
• InChiKey: SCKUMUAJSWJVDN-UHFFFAOYSA-N

物化性质

• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Hepatitis B antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10738035B2

  公开（公告）日：2020-08-11

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： X-A-Y-Z-L-R1 (I) 其可抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒 HBV 生命周期的功能，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给受 HBV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 HBV 感染的方法。
• Substituted thiazoles for preventing and/or treating cell or tissue necrosis
  申请人：ELA PHARMA LTD

  公开号：US10968185B2

  公开（公告）日：2021-04-06

  Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis are described. The compounds include thiazoles of Formula II, where G1 is an optionally substituted pyrrolidine, an optionally substituted pyridine, an optionally substituted aryl, an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted imidazolidine, or an optionally substituted pyrazolidine. G3 is or G3 is an optionally substituted alkyl, an optionally substituted aryl or an optionally cyloalkyl. G2 is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted cyloalkyl or an optionally substituted heterocycle. Various applications for the described compounds, and combination therapies are described as well.

  本发明描述了 Cathepsin C、CELA1、CELA3A 和/或其结构相关分子的抑制剂化合物和制剂、包含这些化合物和制剂的组合物及其在抑制和/或预防细胞和/或组织坏死中的用途。这些化合物包括式 II 的噻唑类化合物、 其中 G1 是任选取代的吡咯烷、任选取代的吡啶、任选取代的芳基、任选取代的哌啶、任选取代的哌嗪、任选取代的咪唑烷或任选取代的吡唑烷。G3 是 或 G3 是任选取代的烷基、任选取代的芳基或任选取代的环烷基。G2 是任选取代的烷基、任选取代的芳基、任选取代的环烷基或任选取代的杂环。还介绍了所述化合物的各种应用以及组合疗法。
• Hepatitis B Antiviral Agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160332996A1

  公开（公告）日：2016-11-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO
  申请人：Ela Pharma Ltd

  公开号：US20210309620A1

  公开（公告）日：2021-10-07

  Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.